Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma
Liyan Jiang(Southwest University), Jiaqi Huang(Peking University), Chris Morehouse, Philip Z. Brohawn(Hofstra University), Katie Streicher(AstraZeneca (United States)), Wei Zhu(Ministry of Education of the People's Republic of China), Yihong Yao(University of Science and Technology Beijing), Xiaoxiao Ge(Fudan University), Zhengwei Dong(Tongji University), Xiaolu Yin(AstraZeneca (Singapore)), Koustubh Ranade, Yi Gu, Guanshan Zhu(Shanghai Innovative Research Center of Traditional Chinese Medicine), Brandon W. Higgs(Parker Institute for Cancer Immunotherapy)
Cited by 32
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|Cell|2020|546
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412